Optimistic Buy Rating for Gilead Sciences: Anticipated EPS Growth and Strong Performance in 2024
In a report released yesterday, Mohit Bansal from Wells Fargo maintained a Buy rating on Gilead Sciences (GILD – Research Report), with a price ...
RBC Capital Remains a Hold on Gilead Sciences (GILD)
In a report released on January 21, Brian Abrahams from RBC Capital maintained a Hold rating on Gilead Sciences (GILD – Research Report), with ...
Tuberculosis Clinical Trial Pipeline Appears Robust With 30+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight
DelveInsight's 'Tuberculosis Pipeline Insight 2025' report provides comprehensive global coverage of pipeline tuberculosis ...
BioSpace3d
Almost 5 Years into $5B Galapagos Partnership, Gilead Execs Start Over With New Spinoff
Gilead signed a massive deal with Galapagos. After a restructuring, the pharma is still hunting for the potential it saw at ...